Vbi Vaccines Inc buy marge
Summary
This prediction ended on 27.11.18 with a price of €1.52. The BUY prediction by marge for Vbi Vaccines Inc performed very badly with a performance of -61.06%. marge has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Vbi Vaccines Inc | - | - | - | - |
| iShares Core DAX® | 2.594% | -1.861% | 13.242% | 16.867% |
| iShares Nasdaq 100 | 3.553% | -2.064% | 38.293% | 45.898% |
| iShares Nikkei 225® | 0.687% | -8.704% | 17.510% | 2.760% |
| iShares S&P 500 | 2.209% | -1.988% | 27.632% | 42.955% |
Comments by marge for this prediction
In the thread Vbi Vaccines Inc diskutieren
VBIV continues making progress towards starting a Phase 3 trial for hepatitis B
Summary
VBI Vaccines continues making progress towards starting a Phase 3 trial for hepatitis B.
The recent addition to the Russell 2000 should provide more visibility to the investment community for the small biotech.
The recent stock selloff provides an opportunity to own the biotech at a reasonable value.
As with most small biotechs, VBI Vaccines (VBIV) trades in a volatile manner. The stock now trades some 35% from the yearly highs of $6.60 despite some promising developments for the stock during june.
Last week, the small biotech got positive feedback from the FDA that Sci-B-Vac will not require additional clinical studies to support the Phase 3 study. The company now plans to kickoff the IND in the U.S. and CTAs in Europe and Canada in the 2H of the year.
The key to the story is that the third-generation hepatitis B vaccine has already demonstrated safety and efficacy in over 300,000 patients. The vaccine is approved in the home country Israel of SciVac and 14 other countries.